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Abstract
The unfolded protein response (UPR) and the Akt signaling pathway share several regulatory functions and have the
capacity to determine cell outcome under specific conditions. However, both pathways have largely been studied
independently. Here, we asked whether the Akt pathway regulates the UPR. To this end, we used a series of chemical
compounds that modulate PI3K/Akt pathway and monitored the activity of the three UPR branches: PERK, IRE1 and ATF6.
The antiproliferative and antiviral drug Akt-IV strongly and persistently activated all three branches of the UPR. We present
evidence that activation of PERK/eIF2a requires Akt and that PERK is a direct Akt target. Chemical activation of this novel
Akt/PERK pathway by Akt-IV leads to cell death, which was largely dependent on the presence of PERK and IRE1. Finally, we
show that hypoxia-induced activation of eIF2a requires Akt, providing a physiologically relevant condition for the
interaction between Akt and the PERK branch of the UPR. These data suggest the UPR and the Akt pathway signal to one
another as a means of controlling cell fate.
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Introduction
Akt (also known as protein kinase B or PKB) is a serine/
threonine kinase member of the AGC family of protein kinases,
which plays a central role in growth, proliferation, protein
translation and cell survival [1–3]. Akt is recruited to the plasma
membrane by phosphatidylinositol (3,4,5)-triphosphate (PIP3)
generated by activated PI3K. Once at the membrane, Akt is
phosphorylated on Thr308 [4] by PDK1 and on Ser473 by
mTORC2 [5]. Akt can also be phosphorylated at other sites,
which are important for its kinase activity [6,7]. Activated Akt
phosphorylates multiple targets in the cytoplasm, nucleus,
mitochondria and at the surface of the endoplasmic reticulum
membrane (ER) [8,9]. Deregulation of the Akt pathway is
associated with a variety of human cancers, and mouse models
with activated Akt support its role in cancer development [10–12].
Several inhibitors of the Akt pathway have been developed as
therapeutic treatments, some of which are currently being tested in
clinical trials [13–16]. One of these inhibitors is the benzimidazole
derivative Akt-IV (also known as ChemBridge 5233705 or Akt
inhibitor IV) [17], which has potent anticancer and antiviral
activity [18–20]. Although the direct target of Akt-IV is not
known, it has been proposed to bind the ATP pocket of a kinase
upstream of Akt but downstream of PI3K, possibly that of PDK1
[17]. Akt-IV has been shown to inhibit the phosphorylation and
activity of Akt. However, at low concentrations, Akt-IV promotes
the hyperphosphorylation of Akt [20]. The mechanisms behind
these seemingly contradictory effects of Akt-IV on the Akt protein
and its antiviral and antiproliferative activities are poorly
understood.
Like the Akt pathway, the unfolded protein response (UPR) is
involved in the regulation of metabolism, protein translation, cell
death and survival [21,22], and it is thought to be important in the
development of different malignant neoplasms such as multiple
myeloma, prostate and breast cancer [23,24]. The accumulation
of unfolded proteins in the lumen of the ER triggers a
multipronged signal transduction response aimed at reestablishing
cellular homeostasis. This includes a rapid reduction in the protein
load in the ER, which is accomplished by lowering protein
synthesis and translocation into the ER, and an increase in the
capacity of the ER to fold proteins by upregulating the expression
of foldases and chaperones. If homeostasis cannot be reestablished,
the UPR can induce cell death, probably to protect the organism
from rogue cells that express misfolded proteins. Three ER stress
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transducers have been identified: inositol-requiring protein-1
(IRE1), activating transcription factor-6 (ATF6) and protein kinase
RNA (PKR)-like ER kinase (PERK). These integral membrane
proteins sense the protein folding status in the ER lumen and
communicate this information to cytosolic target proteins that
translocate to the nucleus to modulate gene expression [22,25,26].
The UPR was historically viewed as a stress response system but a
growing body of work suggests that it also functions in the
maintenance of basal cellular homeostasis [21]. In this view, the
UPR could be activated and its output modulated by signals other
than misfolded proteins. In accordance with this notion, P58-IPK
and a novel cytosolic isoform of BIP have been described to
interact and regulate PERK from the cytosolic side [27–29].
Both the UPR and the Akt signaling pathways regulate protein
translation, albeit in opposing ways. Akt promotes translation by
two paths. First, it phosphorylates and activates mTORC1, which
in turn inactivates 4EBP by phosphorylating it in at least four sites
[2]. Unphosphorylated 4EBP blocks translation by binding to the
cap binding protein eIF4E, the rate limiting step in cap-dependent
translation. Second, Akt inactivates the glycogen synthetase kinase
3b (GSK3b), the major kinase that phosphorylates and inactivates
the eukaryotic initiation factor 2 (eIF2) and its activator, the
guanine exchange factor eIF2B [3]. In contrast, the UPR, via
PERK, blocks translation initiation by directly phosphorylating
one of the subunits of eIF2 trimer, eIF2a. eIF2 containing
phosphorylated eIF2a inhibits eIF2B, preventing further activa-
tion of eIF2 [26]. Although the UPR and the Akt pathway have
long been known to regulate similar cellular systems and influence
cell fate, a functional link between the two pathways has only
recently emerged. The UPR has been reported to activate [30–35]
or inhibit [36–38] the Akt pathway depending on the nature and
severity of the ER insult. It was recently proposed that Akt
phosphorylates and inhibits PERK [39], although the role of the
Akt pathway in regulating the UPR remains poorly understood.
In this work we used a series of chemical modifiers of the Akt
pathway and tested whether Akt signaling can regulate the UPR.
We found that Akt-IV strongly activates all the three branches of
the UPR, with the PERK branch showing a dependence on the
presence and activity of Akt. Our results suggest that Akt is a
cytosolic regulator of the UPR and that the signaling between
these two pathways may control the balance of pro-survival and
pro-apoptotic signals thereby regulating cell fate decisions.
Results
Pharmacological modulation of Akt with Akt-IV activates
the UPR
To test the hypothesis that the Akt pathway regulates the UPR,
we used a series of small molecules that differentially target the
PI3K/Akt pathway (Fig. 1A, B). We used the classic PI3K
inhibitor LY294002 [40], Akt-VIII, a direct and selective inhibitor
of Akt [41], and Akt-IV. We evaluated the effects of these drugs on
the activation of the three branches of the UPR in HEK293T cells
in culture.
Akt-IV triggered a strong and sustained (2 to 24 h) activation of
the IRE1 branch, as detected by monitoring the splicing of Xbp-1
mRNA by RT-PCR (Fig. 2A). Neither LY294002 nor Akt-VIII
showed any effects on Xbp-1 mRNA splicing. We evaluated the
activation of the ATF6 branch by measuring the cleavage of a
FLAG-tagged ATF6 by western blot (WB) (Fig. 2B) and the re-
localization from the ER to the nucleus of a YFP-ATF6 reporter
(Fig. S1A). Akt-IV induced both the cleavage of ATF6-FLAG
(Fig. 2B) and the re-localization of the fluorescent reporter (Fig. 2C
and Fig. S1B). In contrast, neither LY294002 nor Akt-VIII
induced the cleavage of ATF6-FLAG (Fig. 2B). Finally, we found
that Akt-IV rapidly activated PERK, as assessed by a mobility shift
in an SDS-PAGE gel, and the phosphorylation of the PERK
target eIF2a (Fig. 2D and 2E). As with the IRE1 and ATF6
branches, LY294002 and Akt-VIII had little or no effect on the
PERK branch (Fig. 2D). Even at longer incubation times these
compounds failed to activate the PERK branch at levels
comparable to those of Akt-IV (Fig. S2). As expected, all three
compounds inhibited the phosphorylation of Akt at Ser473 and of
its downstream target GSK3b at Ser9 (Fig. 2D), making the effects
of Akt-IV on the UPR all the more striking.
We noted that just before PERK branch activation, Akt-IV
caused an early transient activation of Akt, as assessed by the
increase in phosphorylation of Ser473 of Akt and on Ser9 of
GSK3b (Fig. 2D). This activation peaked between 1 and
5 minutes post stimulation with Akt-IV and was specific to this
compound since neither LY294002 nor Akt-VIII provoked such
behavior (Fig. 2D). If this transient activation of Akt is important
for the induction of eIF2a phosphorylation needs further
confirmation.
eIF2a phosphorylation induced in response to Akt-IV
depends on PERK and Akt but not on PI3K
Since all three compounds work as Akt inhibitors (Fig. 2D), but
only Akt-IV activates the UPR, we tested the possibility that Akt-
IV regulates the UPR in an Akt-independent manner. To do that,
we evaluated the effects of Akt-IV on mouse embryonic fibroblasts
(MEFs) lacking Akt1 and Akt2, two of the three isoforms of Akt
(Akt DKO, Fig. S3). These cells have no basal activation of Xbp-1
mRNA splicing nor have they increased basal PERK activity as
judged by eIF2a phosphorylation. Treatment of Akt DKO cells
with Akt-IV induced the splicing of Xbp-1 as well as the mobility
shift of PERK to a similar extent as in wild type MEFs (Fig. 3A
and 3B) indicating that these effects are independent of Akt1 and
Akt2. However, the absence of these two isoforms impaired the
capacity of Akt-IV to induce the phosphorylation of eIF2a (Fig. 3B)
showing that in the case of the effect on eIF2a, Akt1 or Akt2
kinases were required. The remaining Akt and pAkt signal
observed by western blot and immunofluorescence in these cells
(Fig. 3B and Fig. S3) is likely due to the fact that Akt DKO cells
still express Akt3. To test whether the kinase activity of Akt is
required as well, we transfected wild type MEFs with a vector
containing a dominant negative kinase dead allele of Akt (HA-Akt-
KM) [42] and determined the effect of Akt-IV on eIF2a
phosphorylation. As in Akt DKO cells, the phosphorylation of
eIF2a induced by Akt-IV was greatly reduced in cells overex-
pressing HA-Akt-KM compared to wild type cells (3 fold decrease
in peIF2a/eIF2a levels compared to control, Fig. 3C) whereas the
mobility shift of PERK was unaffected. Moreover, over-expression
of wild type HA-Akt potentiated the effect of Akt-IV on eIF2a
phosphorylation (3 fold increase in peIF2a/eIF2a levels compared
to control, Fig. 3C), without affecting phosphorylation of eIF2a in
untreated cells.
Thus far, we have shown that Akt is necessary for eIF2a
phosphorylation, but not for the mobility shift of PERK. This
raises the possibility that Akt might cause this effect in a PERK
independent manner. In fact, eIF2a is known to be phosphory-
lated independently of the UPR by GCN2, HRI and PKR [43].
To test whether PERK was the kinase responsible for phosphor-
ylating eIF2a in the presence of Akt-IV, we treated PERK knock
out MEFs (PERK2/2) with Akt-IV (Fig. 3D). We found that the
ability of Akt-IV to induce eIF2a phosphorylation was greatly
impaired in PERK2/2 MEFs as compared to wild type cells.
AKT Stimulates PERK/eIF2alpha
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The residual phosphorylation of eIF2a visible at later time points
(1 h) is likely due to one or more of the other eIF2a kinases [44].
Our data are consistent with a model in which Akt-IV promotes
activation of the PERK/eIF2a branch by triggering Akt kinase
activity. To test whether the effects of Akt-IV on PERK and eIF2a
require the canonical activation of Akt by PI3K, we pre-treated
wild type MEFs with the PI3K inhibitor LY294002 before
stimulating with Akt-IV. As expected, this pre-treatment inhibited
the phosphorylation of Akt on Ser473 (Fig. 3E). However, it did
not affect the ability of Akt-IV to induce the phosphorylation of
eIF2a (Fig. 3E).
Taken together, these results demonstrate that the effect of Akt-
IV on eIF2a phosphorylation is PI3K-independent but Akt- and
PERK-dependent.
PERK is an Akt substrate
One possibility is that the eIF2a phosphorylation elicited by
Akt-IV is due to the activation and phosphorylation of PERK by
Akt or one of its substrates. Alternatively, Akt and PERK could act
in parallel, such that the phosphorylation of eIF2a in the presence
of Akt-IV requires both. If the former model were true, PERK
might be a direct target of Akt, what could be detected in an in vitro
kinase assay. In support of this notion, sequence analysis revealed
that while neither IRE1 nor ATF6 contain putative cytosolic Akt
phosphorylation sites, human PERK contains eight sequences that
match the Akt consensus sequence (RxRxxS/T) [45]. Seven of
these sequences, conserved in rats and mice, are located in its
cytosolic domain (Fig. 4A) and thus are accessible to Akt.
Interestingly, three of these sites (human S554, S1093 and
S1095) have been found to be phosphorylated in vivo according
to PhosphoSitePlusH [45,46]. An in vitro kinase assay with the wild
type HA tagged Akt1 kinase domain immunoprecipitated from
transfected HEK293T cells and a recombinant catalytically
inactive fragment of PERK (aa 537 to 1114) revealed that,
indeed, Akt can phosphorylate PERK (Fig. 4B). Immunoprecip-
itated kinase dead HA-tagged Akt1 kinase domain failed to
phosphorylate PERK, confirming the dependence on Akt activity
(Fig. 4B).
Supporting an in vivo role of Akt in phosphorylating PERK,
fluorescence microscopy experiments with Akt1-CFP and the ER
membrane marker ATF6-YFP confirmed previous reports that, in
addition to localizing to the cytosol, nucleus and plasma
membrane, Akt localizes to the ER membrane (Fig. S4).
Furthermore, we detected co-localization of PERK and phos-
phorylated Akt substrates in cells transfected with myc-PERK and
immunostained with an anti-myc antibody and an antibody that
Figure 1. Strategy. (A) Chemical structure of the compounds targeting the PI3K/Akt pathway used in this study. (B) Scheme of Akt signaling
pathway, which regulates cell survival, showing the point of action of the drugs shown in A. Akt phosphorylation and activation result from its
recruitment to PIP3 at plasma membrane, after which it exerts cytoplasmic and nuclear functions. Accumulation of PIP3 classically follows ligand (L)
binding to tyrosin kinase cell-surface receptors (RTK), adapter proteins (AP) recruitment to RTK and finally, PI3K activation to phosphorylate PIP2 to
PIP3. While Akt can be activated by the UPR it is not known if Akt can also regulate the UPR.
doi:10.1371/journal.pone.0069668.g001
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Figure 2. Pharmacological modulation of Akt with Akt-IV activates all three UPR branches: PERK responds first. (A) When activated,
IRE1 processes Xbp1 mRNA by a non-conventional cytoplasmic splicing reaction, changing Xbp1 open reading frame. HEK293T cells were treated with
Akt-IV (10 mM), Akt-VIII (5 mM) or LY294002 (20 mM) for the indicated times. Xbp1 mRNA splicing was detected by RT-PCR. Xbp1s: spliced form
(activated IRE1); Xbp1u: unspliced form (inactive IRE1). (B) When activated, ATF6 translocates to the Golgi apparatus where it is cleaved to release a
fragment that enters the nucleus where it functions as a transcription factor. HEK293 cells were transfected with ATF6-Flag plasmid and 24 h later
they were treated with Akt-IV (10 mM), Akt-VIII (5 mM), LY294002 (20 mM), or thapsigargin (Tg; 100 nM) for the indicated times. Western blots (WB)
using antibodies against FLAG and actin are shown for every case (B, upper panel). ATF6: uncleaved protein; ATF6f: cleaved form. (C) HEK293T cells
were transfected with a plasmid that expresses the YFP-NLS-mATF6short reporter (top, see Fig. S1A for details). Forty-eight hours post-transfection
cells were treated for the indicated times with Akt-IV and then fixed, DNA was stained with DAPI and cells were imaged (lower panel); Yellow, YFP-
ATF6; Blue, DNA; scale bar, 5 mm. For all cases cells treated with DMSO were used as a control (Control). (D) When activated, PERK is
autophosphorylated at multiple residues and activated to phosphorylate eIF2a. HEK293T cells were treated with Akt-IV (10 mM), Akt-VIII (5 mM) or
LY294002 (20 mM) for the indicated times. Protein extracts were analyzed by WB using the indicated antibodies. Data in the plot corresponds to ratio
of phosphorylated total abundance of each of the indicated proteins (normalized to the initial value) in cells treated with the indicated drugs for
different times. Error bars correspond to the standard error of three independent experiments. (E) HEK293T cells were treated for 5 h with Akt-IV.
peIF2a abundance was detected by immunofluorescence. Green, peIF2a; Blue, DNA; scale bar, 5 mm. Data are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0069668.g002
Figure 3. Akt-IV stimulation of eIF2a phosphorylation is Akt- and PERK- dependent but PI3K-independent. (A) MEF WT or Akt DKO
cells were treated with Akt-IV (IV; 10 mM) for the indicated times. Xbp1 mRNA splicing was detected by RT-PCR. Xbp1s: spliced form (activated IRE1);
Xbp1u: unspliced form (inactive IRE1). (B) MEF WT or Akt DKO cells were treated with Akt-IV (IV; 10 mM) for 1 h. Protein extracts were analyzed by WB
using the indicated antibodies. The fold change in peIF2a/eIF2a ratio induced by Akt-IV was quantified for three independent experiments. On
average, this fold change was reduced to 15% of the original effect in MEF Akt DKO cells compared to WT cells (11.0 vs 2.6). (C) MEF WT cells were
transfected with HA-Akt or HA-Akt KM plasmids. Forty-eight hours post-transfection cells were treated with DMSO (C) or with Akt-IV (IV; 10 mM) for
1 h. A GFP expressing plasmid was used as a transfection control. Protein extracts were analyzed by WB using the indicated antibodies. (D) MEFs WT
or PERK2/2 were treated with Akt-IV (IV; 10 mM) for the indicated times. Protein extracts were analyzed by WB using the indicated antibodies. (E)
HEK293T cells were pretreated with DMSO (C) or LY294002 (LY; 20 mM) for 30 min and then treated for 1 h with DMSO, or Akt-IV (without removing
the corresponding pre-treatment). Protein extracts were analyzed by WB using the indicated antibodies. Data are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0069668.g003
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Figure 4. Akt is a PERK kinase. (A) Human PERK gene containing eight sequences that match the Akt consensus (RxRxxS/T) seven of which are
located in its cytosolic domain (black bar). Green: Akt consensus sequence. Red/Yellow: Akt phosphorylation site. (B) WT and KM HA-Akt mutant
AKT Stimulates PERK/eIF2alpha
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recognizes proteins containing a phosphorylated Akt target motif
(RxRxxS*/T*) [47] (Fig. 4C). In untreated cells, we detected a
structured reticulated cytoplasmic staining with the phospho-Akt
substrate antibody. The rather strong signal is likely due to high
Akt activity normally present in HEK293T cells [48]. At the same
time, the PERK-myc signal was detected in only a few cells due to
the low transfection efficiency of this construct. The time-course of
the signal revealed by the phospho-Akt substrate antibody showed
a peak and decline behavior: after an initial increase seen
15 minutes post treatment, the signal diminished to levels below
those seen in untreated cells. This behavior is similar to what we
observed by western blot using anti phospho-Ser473-Akt (Fig. 2D),
supporting the idea that this antibody was a good reagent to follow
in vivo Akt activity. In contrast to the majority of cells, those cells
that overexpressed PERK-myc did not exhibit this peak and
decline behavior. In these cells, the phospho-Akt substrate signal
concentrated in the same spots where the myc-signal was detected.
These results indicate that PERK might be a direct target of Akt in
vivo.
Akt-IV induces apoptosis in a UPR-dependent manner
Both the Akt pathway and the UPR control cell fate by inducing
pro-survival and/or pro-apoptotic signals. Akt-IV has also been
described to induce cell death in different cell types [49–52]. To
determine the effects of Akt-IV on apoptotic cell death in our
system, we treated HEK293T cells for 7 hours with Akt-IV and
determined by WB the extent of caspase 3 and PARP cleavage.
Akt-IV caused strong activation (cleavage) of caspase 3 and PARP,
which were blocked by the caspase inhibitor ZVAD (Fig. 5A).
Consistent with these results, we found that Akt-IV treatment
induces the formation of cell blebs (Fig. 5B). These transient
globular protrusions of the plasma membrane are seen at the onset
of the certain stress-associated processes, such as cell injury, cell
invasion, hypoxia, high concentrations of free radicals and
apoptosis in some cell lines [53]. Interestingly, Akt-YFP transiently
localizes to these blebs in HeLa cells within 15 minutes of
treatment with Akt-IV (Fig. 5C). Consistently, phosphorylated Akt
substrates and eIF2a also exhibit a transient enrichment in cell
blebs after treatment with Akt-IV treatment (Fig. 5D and 5E), but
not with other inhibitors such as Akt-VIII (Fig. S5).
To determine the role of the UPR in the cell death induced by
Akt-IV, we evaluated the viability of wild type, IRE1 (IRE12/2)
and PERK (PERK2/2) knock out MEFs using a propidium
iodide incorporation assay measured by flow cytometry. Cell death
induced by a 12 h treatment with Akt-IV was greatly reduced in
the absence of IRE1 or PERK (Fig. 5F), indicating that one of the
mechanisms by which Akt-IV induces cell death is UPR
dependent.
Akt mediates PERK/eIF2a activation induced by hypoxia
The internal environment of solid tumors can be hypoxic and
can lead to the activation of mechanisms within the tumor to cope
with this stress. In general, adaptation to hypoxia is associated to
poor response to therapy [54]. During hypoxia, Akt is activated by
phosphorylation of Akt in the non-canonical Thr450 by JNK
kinase [55,56]. In the same conditions, eIF2a is phosphorylated in
a PERK-dependent manner [57]. Furthermore, hypoxia is
associated with cell blebbing and cell death [58]. Thus, given
our results, we hypothesized that Akt might be required for eIF2a
phosphorylation during hypoxia.
To test this hypothesis, we incubated wild type and Akt DKO
MEF cells in low oxygen conditions (0.1% O2) for 1, 2 or 4 hours
and evaluated the levels of eIF2a phosphorylation. In wild type
MEFs, hypoxia induced an increase in phosphorylated eIF2a, but
not a PERK mobility shift. It is possible that PERK autophos-
phorylation under these conditions is either transient or low.
However, in Akt DKO MEFs, hypoxic conditions did not affect
neither PERK nor eIF2a phosphorylation (Fig. 6A). This result
supports our idea that Akt mediates PERK/eIF2a activation
during hypoxia.
Discussion
Here we report the finding of a link that connects Akt with the
PERK branch of the UPR. Our results also shed light into the
molecular mechanism of action of Akt-IV, a drug with anticancer
and antiviral properties with therapeutic potential. We provide
evidence supporting the idea that a non-traditional activation of
Akt leads to PERK-dependent phosphorylation of eIF2. And more
important, we also show that this connection is relevant during a
physiological condition such as hypoxia.
Recently, Mounir et al. provided initial evidence that Akt
regulates PERK signaling [39]. Contrary to our results, the
authors reported that Akt phosphorylates and inhibits PERK
function. They observed higher levels of eIF2a phosphorylation in
Akt DKO MEF cells compared to wild type cells, consistent with
Akt being a PERK inhibitor. We have not observed these
differences (Fig. 3B), although our source of knock out cells was
different [59,60]. In contrast, we found that the overexpression of
a dominant negative form of Akt in wild type MEFs largely
blocked eIF2a phosphorylation in response to Akt-IV, consistent
with a stimulatory, rather than an inhibitory, action of Akt kinase
over PERK (Fig. 3C). Additionally, the authors described that
treatment with other Akt inhibitors like Akt-VIII and LY294002
also induced phosphorylation of eIF2a after several hours of
treatment. We only detected an effect using the Akt-IV compound
(occurring in minutes), with marginal effects using the other Akt
inhibitors. It is worth mentioning that they used a very high
concentration of Akt-VIII (ten times higher than us and more than
twenty times higher than in the paper that originally described
Akt-VIII [41]). One potential explanation for our discrepancies is
that Akt might phosphorylate different residues of PERK
depending on the cell context; some of these could be stimulatory
while others inhibitory. This idea would be consistent with the
presence of several consensus sites for Akt phosphorylation in the
cytosolic domain of PERK (Fig. 4A), and some of which have been
shown to be phosphorylated in vivo [46,61]. It has been shown that
in some cell contexts a prolonged treatment with PI3K inhibitors
reactivates Akt to some extent [62]. Thus, the delayed effect of
Akt-VIII and LY294002 on eIF2a reported by Mounir et al. may
be due to a nontraditional reactivation of Akt instead of inhibition.
Further work will be needed in order to address this issue.
Nonetheless, it seems now confirmed that Akt targets and
phosphorylates PERK modulating its activity and establishing a
connection between these two pathways.
protein was incubated with 10 mCi of [c-32P] ATP for 30 min and with 1 mg of GST or PERK GST protein as substrate. Phosphate incorporation was
analyzed by SDS-PAGE and autoradiography. Akt levels were determined by WB while GST-PERK levels were revealed by Coommassie blue staining.
(C) HEK293T cells were transfected with pCDNA-Myc-PERK and treated for 15 min with Akt-IV (10 mM). Cells were fixed and immunostained for pAkt
substrate and Myc tag. Green, pAkt substrate; Red, Myc-PERK; scale bar, 5 mm. Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0069668.g004
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Figure 5. Akt-IV induces cell blebbing and a UPR dependent cell death. (A) HEK293T cells were treated with DMSO (C), 100 mM of the
caspase inhibitor ZVAD, 10 mM Akt-IV (IV) or both. PERK mobility, eIF2a phosphorylation, Akt phosphorylation on Ser473, caspase 3 cleavage and
PARP cleavage were detected by WB. (B) Transmission images of HeLa cells treated for 15 min with DMSO (15 min) or with Akt-IV (10 mM), with blebs
indicated. Bleb formation was clearly observed in HeLa and MEF cells but could not be detected in HEK293T cells. (C) YFP channel images of HeLa
cells transfected with pAkt1-YFP plasmid and then treated for the indicated times with Akt-IV (10 mM). Akt1-YFP can be detected in blebs after 15 min
of treatment. (D) HeLa cells were treated for 15 min with Akt-IV. Cells were fixed and immunostained against pAkt substrate/Alexa FluorH 488 and
total eIF2a/Alexa FluorH 594. Green, pAkt substrate; Red, eIF2a; Blue, DNA. scale bar, 5 mm. (E) HeLa cells were treated for different times with Akt-IV
(10 mM) and then cells were fixed and immunostained for pAkt substrate/Alexa FluorH 488; scale bar, 5 mm. (F) MEF WT, IRE12/2 or PERK2/2 were
AKT Stimulates PERK/eIF2alpha
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treated with Akt-IV (10 mM) for 12 h. Cell viability was measured by flow cytometry using propidium iodide. Data are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0069668.g005
Figure 6. A physiological link between Akt and PERK/eIF2a. (A) WT or Akt DKO MEF cells were subjected to normoxia (C) or hypoxia
(0.1%60.1 O2) (H) for the indicated times. Protein extracts were analyzed by WB using the indicated antibodies. The fold change in peIF2a/eIF2a ratio
induced by hypoxia was quantified for two independent experiments. On average, this fold change was reduced to 0, 40 or 60% of the original effect
in MEF Akt DKO cells compared to WT cells (1 h, 2 h and 4 h, respectively). (B) A model summarizing our results. Akt-IV (or other stimuli, such as
hypoxia) targets an unknown kinase, possibly PDK1, triggering apoptotic cell blebbing and activating Akt in a PI3K-independent manner (1).
Subsequently, UPR is activated (2). Akt presence and activity are necessary for eIF2a phosphorylation due to the existence of a connection between
Akt and PERK/eIF2a signaling pathways. IRE1 (4) and ATF6 (5) are activated are later times. At the end, activation of IRE1 and PERK and
dephosphorylation of Akt and GSK3b are associated with cell death (6).
doi:10.1371/journal.pone.0069668.g006
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We found that in response to Akt-IV, cells develop cell blebs, to
which Akt relocalizes in a transient manner, at a time coincident
with the onset of eIF2a phosphorylation (Fig. 2C and 5B–C).
Determining if the formation of these blebs is important for this
action of Akt will require future work. Nevertheless, this finding
supports the current view that Akt-IV probably targets PDK1
[17], since it has been shown that PDK1 is involved in cell
blebbing [63]. In the same line, though it needs further
confirmation, it seems possible that the activation of the UPR by
Akt-IV is via PDK1. In support of this hypothesis, other
pharmacological modulators of PDK1 also activate the UPR
pathway [64–66]. Since these compounds, like Akt-IV, activate
Akt1 independent branches (such as IRE1), it seems likely that
PDK1 targets the UPR via Akt dependent and independent
pathways.
Several non-canonical mechanisms of Akt activation have been
recently reported, such as Akt ubiquitination and Akt phosphor-
ylation in residues different from Thr308 and Ser473. In fact,
many kinases, including JNK, Ack1, ERK, CaM kinase and PKA
are able to phosphorylate Akt, and some of them do so
independently from PI3K activity [7,52,67–71]. Remarkably, in
the case of non-traditional activation of Akt induced by Akt-IV,
because of the induced eIF2a phosphorylation, it would promote
translation inhibition, contrary to the classic function of Akt in
stimulating protein synthesis. Rapid and transient activation of the
classic Akt pathway (phosphorylation in S473 and of Akt major
target GSK3b) precedes persistent activation of PERK/eIF2a
pathway, which lasts even after inhibition of Akt (Fig. 2D). This
can be explained both by a persistent non-canonical activation of
Akt (independent of S473 phosphorylation) and/or by a transient
non-canonical activation of Akt, which phosphorylates alternative
targets like PERK, which in turn displays a low dephosphorylation
rate.
We speculate that both cell death and translation inhibition
induced by Akt-IV could be associated with either the late Akt
dephosphorylation at S473, as has been described by the group of
Luo et al [72] or with a non-canonical activation Akt, directing its
kinase activity to alternative targets, such as PERK. We show that
the absence of PERK greatly reduces cell death induced by Akt-
IV, further supporting this alternative (Fig. 5F). Independently of
whether IRE12/2 and PERK2/2 cells have a reduced
apoptosis potential or not, what it is clear is that Akt-IV needs
the presence of these proteins to induce cell death. Here, we also
show that Akt-IV displays effects that are independent of Akt, such
as IRE1 dependent Xbp1 mRNA splicing and PERK electropho-
retic mobility shift. We speculate that Akt-IV –perhaps mediated
by PDK1 as suggested above- might in fact cause protein
unfolding at the ER lumen in an Akt independent manner,
affecting all the branches in different manners. In this regard, the
shift induced by Akt-IV on PERK mobility in an SDS-PAGE
persisted on Akt DK0 cells as well as in cells transfected with HA-
Akt-KM (Fig. 3B and 3C), indicating that the phosphorylation of
PERK induced by Akt-IV responsible for the shift is independent
of the presence of Akt1/2. In addition, this result also showed that
the classic mobility shift might not always indicate full PERK
activation, since in this case, even though the PERK band shifted,
phosphorylation of eIF2a was greatly reduced. Thus, we speculate
that Akt signaling activates PERK in a manner that might
complement the activation associated with the classical mobility
shift.
The design of drugs that target different components of the Akt
signaling pathway is of great value for the therapeutic treatment of
cancer [13–17,50,73,74], and Akt-IV has been shown to exhibit
potent anticancer and antiviral activity [13–17,50,73,74]. For this
reason, new analogues of Akt-IV have been designed with
enhanced antiviral/antiproliferative activity and low cytotoxicity
in normal cells [50]. Dunn et al. found that Akt-IV elicited Akt
phosphorylation and blocked viral replication. They proposed that
Akt-IV antiviral activity was unrelated to its action on Akt [17,20].
They based this conclusion solely in their observation that other
drugs, like LY294002, neither have this antiviral action nor
prevented it, despite blocking Akt phosphorylation, similar to what
we observed for Akt-IV and the UPR activation (Fig. 2A–D).
However, using MEF Akt DKO cells and a dominant negative
form of Akt (Fig. 3A and B), we found that activation of the PERK
branch actually required Akt kinase activity. In this regard, it is
worth mentioning that the UPR and PERK in particular, play an
important role in the expression of viral proteins [75–77]. Thus, in
the light of our results it would be interesting to test if the antiviral
activity of Akt-IV does indeed depend on Akt especially on this
newly discovered Akt/PERK pathway.
In summary, our data suggests that Akt-IV triggers cell blebbing
and a rapid and non-traditional activation of Akt, which stimulates
the PERK branch of the UPR. Akt-IV also activates the IRE1 and
ATF6 branches, maybe through the promotion of unfolded
proteins at the ER. Akt-IV also promotes a late inhibition of Akt
traditional activity (evaluated by loss of pAkt S473 and pGSK3b
S9 phosphorylation) which in combination with the UPR
eventually result in cell death via apoptosis (Fig. 6B). It has been
previously shown that PERK-mediated phosphorylation of eIF2a
during hypoxia is important for long-term survival [57]. Here we
found that Akt is necessary for eIF2a phosphorylation in these
conditions (Fig. 6A), providing an important physiological context
for the Akt-PERK interaction. The link between Akt and UPR
pathways suggests a constant feedback between them, since ER
stress and UPR have already been shown to alter Akt activity
[24,35,78,79]. This feedback provides a mechanistic basis for
previous suggestions that UPR plays a key role in the maintenance
of basal cellular homeostasis to a level far beyond to its role in ER
protein folding [21,24]. Cross-talk between these key signaling
cascades is not surprising since both pathways play crucial
functions in apoptosis, cell survival, protein translation and tumor
growth [10–12,23,24]. Consistently, the connection between ER
stress and the Akt downstream target mTOR was recently
highlighted [80]. We suggest that the Akt/UPR connection
functions as a master control mechanism of cell decision-making,
illustrating the remarkable flexibility of signaling pathways.
Materials and Methods
Cell Culture
HEK293T, HEK293, MEF, HeLa, MCF7 and COS7 cells
were grown in high glucose (4.5 g/L glucose) Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen) supplemented with 10%
fetal bovine serum (FBS) and penicillin/streptomycin (100 units/
ml and 100 mg/ml respectively, Invitrogen) in all cases. HEK293T
and MEF cells also have 110 mg/L of sodium pyruvate. MEF WT
and Akt DKO were obtained from Yang Luo, et al [59]. MEF WT,
IRE12/2 and PERK2/2 [81] were provided by Walter, P.
(UCSF, USA). MEF GCN22/2 [82] were provided by Koromilas,
A (Mc Hill University, Canada).
Chemicals, reagents and treatments
Akt-IV (10 mM), Akt-VIII (5 mM) and LY294002 (20 mM) were
obtained from Calbiochem. Thapsigargin (Tg) was obtained from
Sigma. Caspase Inhibitor Z-VAD-FMK (ZVAD) (100 mM) is from
Promega. The cells were plated (26105 cells per well for 6 well
plates, 46104 cells per well for 24 well plates and 16104 cells per
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well for 96 well glass-bottom imaging plates) and grown for 24 h
before transfection and/or treatment for the specified times.
Plasmids and Transfections
ATF6-FLAG reporter [83], pCMV6-HA-Akt and pCMV6-
HA-Akt KM [84] has been previously described. pGEX4T-1-
PERK K618R, used for bacterial expression, pCDNA-Myc-
PERK and pBABE-Myc-PERK used for eukaryotic cell expres-
sion were obtained from Addgene. All cell lines were transfected
with Effectene (Qiagen) or Lipofectamine (Invitrogen) according
the manufacture instructions.
Construction of fluorescent reporters
YFP-NLS-mATF6short reporter was constructed by PCR
amplification of mouse ATF6 transmembrane and ER luminal
domains (short ATF6). Forward primer contained an SV40 NLS
sequence upstream of ATF6 specific sequence. This PCR product
was digested with HindIII and cloned into pEYFP-C1 (Clontech).
The primers used were as follows:
mATF6 For:
59 AATAAAAGCTT TCGCCACC ATGCCAAAAAA-
GAAGCGTAAGGTCGACGAGGTGGTGTCAGAG 39
mATF6 Rev:
59 AATAAAAGCTTCTGCAACGACTCAGGGAT 39
Akt1-CFP fusion proteins were constructed by PCR amplifica-
tion of mouse Akt1 followed by digestion with HindIII and cloning
into pECFP-N1 (Clontech). The primers used were as follows:
mAkt1-FP For:
59 AATAAAAGCTT TCGCCACCATGAACGACGTAGC-
CATT G 39
mAkt1-FP Rev:
59 AATAAAAGCTTGGCTGTGCCACTGGCTGAG 39
RNA Isolation and RT-PCR Amplifications
RNA purification from cultured cells was carried using the
RNAeasy kit, (Qiagen, Germany). PolyA mRNA was reverse-
transcribed using M-MLV reverse transcriptase (Invitrogen,
Carlsbad, CA). cDNA was used as template for PCR amplification
across the fragment of the Xbp-1 cDNA bearing the intron target
of IRE1a ribonuclease activity. Primers used included: murine
Xbp-1 sense 59-GAACCAGGAGTTAAGAACACG-39 and anti-
sense 59-AGGCAACAGTGTCAGAGTCC-39; human Xbp-1,
sense 59-TTACGAGAGAAAACTCATGGC-39 and antisense 59-
TCCAAGTTGTCCAGAATGC-39. PCR conditions were: 95uC
for 5 min; 95uC for 30 sec; 56uC for 30 sec; 72uC for 30 sec; 72uC
for 5 min with 30 cycles of amplification. PCR products were
resolved on a 3% agarose/16TAE gel.
Western Blot Analysis
Protein extract preparation and western blot analysis were
performed as previously described [85]. Primary antibodies used
against PERK, peIF2a S51, eIF2a, pAkt S473, Akt, pGSK3b S9,
HA, pAkt substrate, PARP and caspase 3 (all from Cell Signaling
Technology), GSK3b (clone H76, Santa Cruz), FLAG and actin
(1/10000) (Sigma), all were used at 1/1000 at least that something
else were indicated. To quantify the bands obtained via Western
blot analysis, we applied ImageJ software based analysis (http://
imagej.nih.gov/ij/).
Cell Imaging and Immunofluorescence
For fluorescent reporter assays and immunofluorescence, cells
were plated into 96 well glass-bottom imaging plates and
transfected -when indicated- 24 h later with lipofectamine
according the manufacter instructions. After treatment, cells were
fixed as described [86] with 4% paraformaldehyde in PBS for
5 min at room temperature, washed twice with PBS, permeabi-
lized for 5 min with 0.2% Triton X-100 in PBS and blocked for
30 min with 3% BSA in PBS. After incubation for 1 h with
primary and secondary antibodies (Alexa 594 or Alexa 488 labeled
anti-mouse antibodies) in blocking solution for 1 h each, cells were
extensively washed with PBS and nuclei were stained with DAPI.
Images were captured on an Olympus IX-81 fluorescence
microscope equipped with a 606 oil immersion objective and a
Coolsnap HQ2 CCD camera (Photometrics). Acquisition was
carried out with MetaMorphH Microscopy Automation & Image
Analysis Software.
Expression of recombinant proteins,
immunoprecipitation and PERK in vitro Phosphorylation
Assays
Expression and purification of GST and GST fusion proteins as
well as Akt in vitro kinase assays were performed as described [86].
Briefly, GST and GST-PERK (K618R) were over-expressed in
the E. coli Rosetta pLysS BL21 strain (Novagen) by incubation at
37uC until the optical density was 0.5 and induction with
isopropyl-b-thiogalactopyranoside during 3 h. Following bacterial
lysis, soluble proteins were affinity purified under nondenaturing
conditions, on a glutathione-sepharose 4B-CL resin (Amersham-
Pharmacia) according to the manufacturer instructions. For Akt
kinase assays, HEK293T in 100-mm plates were transfected with
pCMV6-HA-Akt, pCMV6-HA-Akt KM or were mock transfect-
ed. After 48 h cells were washed with cold PBS and lysed at 4uC in
Akt lysis buffer (20 mM Tris-HCl pH 7.5, 137 mM NaCl, 1%
Triton X100, 10% glycerol, 20 mM NaF, 2 mM sodium
vanadate, 1 mM DTT and 25 mM b-glycerophosphate plus a
protease inhibitor cocktail (Roche)). WT and KM mutant HA-Akt
were immunopurified from cleared lysates with an anti-HA
antibody (MMS-101R, Covance) and Gamma-Bind Sepharose
beads (Santa Cruz Biotechnology). Lysates from mock transfected
cells were subject to the same procedure and used as a negative
control. After extensive wash, the immunoprecipitate was incu-
bated with 10 mCi of [c-32P] ATP for 30 minutes in 30 ml kinase
buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 10 mM MnCl2,
1 mM DTT, 20 mM ATP) at 25uC using 1 mg of GST or GST
fusion protein as substrate. The reactions were terminated by
addition of 56sample buffer and boiling. Phosphate incorporation
was analyzed by sample electrophoresis on a 12% SDS-PAGE and
autoradiography.
Cell viability assay
After the corresponding treatment the cells were incubated with
1 mg/ml of propidium iodide (PI). PI incorporation was measured
after 15 min by flow citometry using FACScanto II cytometer and
FACS DIVA program.
Hypoxia induction
MEF WT and Akt DKO cells were plated in p6 culture dishes
at a density of 16105 cells/ml. After approximately 18 h the
culture dishes were placed in the hypoxic culture chamber
(BioSpherix). The oxygen concentration in the chamber was
maintained with an oxygen sensor (Proox Model 110) and a
carbon dioxide sensor (ProCO2 model 120).
Supporting Information
Figure S1 Akt-IV induces the translocation of the ATF6
reporter in different cell lines. (A) Diagram of pEYFP vector
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used for pYFP-NLS-mATF6short construction. ATF6 transmem-
brane (TmD) and luminal domains (LD) downstream of YFP were
linked to the SV40 nuclear localization signal (NLS). The sites for
ATF6 protease cleavage (S1P and S2P) are depicted. HeLa cells
were transfected with YFP-NLS-mATF6short and GalT1-CFP
plasmids, to label the Golgi apparatus. After 48 h, cells were
treated with the ER stressor Tg for 4 h and then fixed and
immunostained with antibodies against calnexin/Alexa FluorH
594, to label ER. Yellow, YFP-NLS-mATF6short; Red, Calnexin
(ER); Cyan, GalT1-CFP (Trans-Golgi); Blue, DNA; scale bar,
5 mm. The images showing ATF6 reporter in the nucleus (middle
panel) or in the Golgi (bottom panel) are representative of the
population response. (B) MCF7 (upper panel) and COS7 (lower
panel) cells were transfected with the YFP-NLS-mATF6short
plasmid. After 48 h, cells were treated with Akt-IV for 5 h and
then fixed and imaged; scale bar, 5 mm. Data are representative of
at least three independent experiments.
(TIF)
Figure S2 Traditional inhibitors of the Akt pathway
have marginal or no effect on PERK/eIF2a activation
even at long times. HEK293T cells were treated with DMSO
(control), LY294002 (20 mM), Akt-VIII (5 mM) or Akt-IV (10 mM),
for the indicated times. Protein extracts were analyzed by WB
using the indicated antibodies. Data are representative of at least
three independent experiments.
(TIF)
Figure S3 Distribution of Akt isoform 3 in Akt DKO
MEFs. WT and Akt DKO MEF cells were fixed and
immunostained with antibodies against (A) Akt/Alexa FluorH
488 or (B) pAkt S473/Alexa FluorH 488. Scale bar, 5 mm. Data
are representative of at least three independent experiments.
(TIF)
Figure S4 YFP-ATF6 and Akt-CFP colocalize in the ER.
(A) Diagram of pECFP-N1 vector used for pAkt1-CFP construc-
tion. (B) HeLa cells were transfected with YFP-NLS-mATF6short
and Akt1-CFP plasmids. After 48 h, cells were fixed and imaged;
scale bar, 5 mm. N: Nucleus; C: Cytosol; ER: Endoplasmic
Reticulum; PM: Plasma Membrane. Data are representative of at
least three independent experiments.
(TIF)
Figure S5 pAkt substrate containing blebs induced by
ATK-IV and Akt-VIII. HeLa cells were treated for 5 min with
Akt-IV (10 mM), Akt-VIII (5 mM) or were mock treated (C). Cells
were fixed and immunostained for pAkt substrate/Alexa FluorH
594; scale bar, 5 mm. The numbers show the percentage of cells
displaying blebs in each condition. Data are representative of at
least three independent experiments.
(TIF)
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